Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Calcitonin gene-related peptide (CGRP) is a validated target for the treatment of episodic migraine. Here we assess the safety, tolerability, and efficacy of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of high-frequency episodic migraine.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Neurol

Title: The Lancet. Neurology

ISSN (Electronic): 1474-4465

ISSN (Print): 1474-4422

Publication date (Electronic): Nov 2015

Volume: 14

Issue: 11

Affiliations

[1 ] Research and Development Department, Teva Pharmaceuticals, Frazer, PA, USA. Electronic address: marcelo.bigal@tevapharm.com.

[2 ] Department of Neurology, Mayo Clinic, Phoenix, AZ, USA.

[3 ] The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

[4 ] Department of Neurology, Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.

[5 ] Statistics Department, Teva Pharmaceuticals, Frazer, PA, USA.

[6 ] Research and Scientific Affairs Department, Teva Pharmaceuticals, Frazer, PA, USA.

[7 ] Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

[8 ] Headache Institute and St Luke's-Roosevelt Hospital Center, New York, NY, USA.

[9 ] Department of Neurology, Albert Einstein College of Medicine, New York, NY, USA.

Article

Publisher Item ID: S1474-4422(15)00249-5

DOI: 10.1016/S1474-4422(15)00249-5

PubMed ID: 26432182

SO-VID: ab243f71-76cc-4861-b0a8-3cd3cd4af5d8

History

Data availability:

Comments

Comment on this article

scite_

Cited by 120

See all cited by